For confirmation purposes, we considered end-point titers of 1 256 or greater as a criterion when only one serum sample was available for diagnosis.
However here we consider end of year treatment outcomes relating to the treatment system rather than individual treatment episodes (unless stated) with opioid and stimulant users having equal opportunity to be in contact with the system at each years' end.
It is important to note that we consider end-to-end achievable rates.
As performance metrics, we considered the end-to-end delay and the average ratios of deadline misses and message losses.
For this reason, we considered the end of the stimulation pulse, where the AIS spike has already been generated, as a moment from which the EPSC latency has to be measured.
Following previous studies, we considered the end of the dawn chorus to be when the female emerged from the nest and engaged in copulation behaviour with the male [23], [30], [31].
We considered all end points at the longest follow-up available in each study.
In several cases for which sponsorship of chemicals was withdrawn due to overlap with international regulatory programs, we considered the end points addressed by existing data.
We considered the end of exposure to be when the husband ceased employment or the marriage was terminated, whichever came earlier.
Hence, we only consider end-to-end delay and do not compute intermediate packet delays (e.g. after k hops).
In addition, we further consider end-to-end traffic delay requirements since the optimization of link weights for load-balancing and energy savings may introduce substantially increased traffic delay after link sleeping.
